Anti-human natural killer cell inhibitory receptor group 2A protein (NKG2A) antibodies
The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desi...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | Bezman, Natalie Rakestraw, Ginger C Bee, Christine Deshpande, Shrikant Jhatakia, Amy D Rangan, Vangipuram S Shao, Xiang Huang, Richard Y Henning, Karla Ann Korman, Alan J Chen, Guodong |
| description | The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_US11274150B2</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>US11274150B2</sourcerecordid><originalsourceid>FETCH-epo_espacenet_US11274150B23</originalsourceid><addsrcrecordid>eNqNjLsOAiEQAGksjPoPa6fFJYIaazQ-EhMbH-2Fw9XbiEAWKPx7r_ADrGaKyfTFTftMVVvexoM3ubBx8CLnkMGic0C-pYZy4A8wWoydwZNDiaA0RA4ZycPkdNwrPQXTvZpwJ0xD0XsYl3D040CMd9vL5lBhDDWmaCx6zPX1LKVaLeRytlbzf5ovsHE4kw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Anti-human natural killer cell inhibitory receptor group 2A protein (NKG2A) antibodies</title><source>esp@cenet</source><creator>Bezman, Natalie ; Rakestraw, Ginger C ; Bee, Christine ; Deshpande, Shrikant ; Jhatakia, Amy D ; Rangan, Vangipuram S ; Shao, Xiang ; Huang, Richard Y ; Henning, Karla Ann ; Korman, Alan J ; Chen, Guodong</creator><creatorcontrib>Bezman, Natalie ; Rakestraw, Ginger C ; Bee, Christine ; Deshpande, Shrikant ; Jhatakia, Amy D ; Rangan, Vangipuram S ; Shao, Xiang ; Huang, Richard Y ; Henning, Karla Ann ; Korman, Alan J ; Chen, Guodong</creatorcontrib><description>The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.</description><language>eng</language><subject>CHEMISTRY ; HUMAN NECESSITIES ; HYGIENE ; INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES ; MEASURING ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PEPTIDES ; PHYSICS ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS ; TESTING</subject><creationdate>2022</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220315&DB=EPODOC&CC=US&NR=11274150B2$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20220315&DB=EPODOC&CC=US&NR=11274150B2$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Bezman, Natalie</creatorcontrib><creatorcontrib>Rakestraw, Ginger C</creatorcontrib><creatorcontrib>Bee, Christine</creatorcontrib><creatorcontrib>Deshpande, Shrikant</creatorcontrib><creatorcontrib>Jhatakia, Amy D</creatorcontrib><creatorcontrib>Rangan, Vangipuram S</creatorcontrib><creatorcontrib>Shao, Xiang</creatorcontrib><creatorcontrib>Huang, Richard Y</creatorcontrib><creatorcontrib>Henning, Karla Ann</creatorcontrib><creatorcontrib>Korman, Alan J</creatorcontrib><creatorcontrib>Chen, Guodong</creatorcontrib><title>Anti-human natural killer cell inhibitory receptor group 2A protein (NKG2A) antibodies</title><description>The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.</description><subject>CHEMISTRY</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES</subject><subject>MEASURING</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PEPTIDES</subject><subject>PHYSICS</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><subject>TESTING</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2022</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNjLsOAiEQAGksjPoPa6fFJYIaazQ-EhMbH-2Fw9XbiEAWKPx7r_ADrGaKyfTFTftMVVvexoM3ubBx8CLnkMGic0C-pYZy4A8wWoydwZNDiaA0RA4ZycPkdNwrPQXTvZpwJ0xD0XsYl3D040CMd9vL5lBhDDWmaCx6zPX1LKVaLeRytlbzf5ovsHE4kw</recordid><startdate>20220315</startdate><enddate>20220315</enddate><creator>Bezman, Natalie</creator><creator>Rakestraw, Ginger C</creator><creator>Bee, Christine</creator><creator>Deshpande, Shrikant</creator><creator>Jhatakia, Amy D</creator><creator>Rangan, Vangipuram S</creator><creator>Shao, Xiang</creator><creator>Huang, Richard Y</creator><creator>Henning, Karla Ann</creator><creator>Korman, Alan J</creator><creator>Chen, Guodong</creator><scope>EVB</scope></search><sort><creationdate>20220315</creationdate><title>Anti-human natural killer cell inhibitory receptor group 2A protein (NKG2A) antibodies</title><author>Bezman, Natalie ; Rakestraw, Ginger C ; Bee, Christine ; Deshpande, Shrikant ; Jhatakia, Amy D ; Rangan, Vangipuram S ; Shao, Xiang ; Huang, Richard Y ; Henning, Karla Ann ; Korman, Alan J ; Chen, Guodong</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_US11274150B23</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2022</creationdate><topic>CHEMISTRY</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES</topic><topic>MEASURING</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PEPTIDES</topic><topic>PHYSICS</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><topic>TESTING</topic><toplevel>online_resources</toplevel><creatorcontrib>Bezman, Natalie</creatorcontrib><creatorcontrib>Rakestraw, Ginger C</creatorcontrib><creatorcontrib>Bee, Christine</creatorcontrib><creatorcontrib>Deshpande, Shrikant</creatorcontrib><creatorcontrib>Jhatakia, Amy D</creatorcontrib><creatorcontrib>Rangan, Vangipuram S</creatorcontrib><creatorcontrib>Shao, Xiang</creatorcontrib><creatorcontrib>Huang, Richard Y</creatorcontrib><creatorcontrib>Henning, Karla Ann</creatorcontrib><creatorcontrib>Korman, Alan J</creatorcontrib><creatorcontrib>Chen, Guodong</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Bezman, Natalie</au><au>Rakestraw, Ginger C</au><au>Bee, Christine</au><au>Deshpande, Shrikant</au><au>Jhatakia, Amy D</au><au>Rangan, Vangipuram S</au><au>Shao, Xiang</au><au>Huang, Richard Y</au><au>Henning, Karla Ann</au><au>Korman, Alan J</au><au>Chen, Guodong</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Anti-human natural killer cell inhibitory receptor group 2A protein (NKG2A) antibodies</title><date>2022-03-15</date><risdate>2022</risdate><abstract>The present disclosure provides isolated monoclonal antibodies (e.g., humanized and human monoclonal antibodies), or antigen-binding fragments thereof, that specifically bind to human natural killer cell inhibitory receptor group 2A (NKG2A) protein with high affinity and exhibit therapeutically desirable functional properties, such as for the treatment of, for example, cancer. Immunoconjugates, bispecific molecules, and pharmaceutical compositions comprising the anti-NKG2A antibodies of the invention are also provided. Nucleic acid molecules encoding the antibodies, expression vectors, host cells, and methods of treatment of, for example, cancer using the antibodies are further provided. Combination therapy, in which an anti-NKG2A antibody in the present disclosure is co-administered with at least one additional agent such as another antibody (e.g., anti-PD-1, anti-PD-L1, and/or anti-CTLA-4 antibodies), is also provided.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_epo_espacenet_US11274150B2 |
| source | esp@cenet |
| subjects | CHEMISTRY HUMAN NECESSITIES HYGIENE INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIRCHEMICAL OR PHYSICAL PROPERTIES MEASURING MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PHYSICS PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS TESTING |
| title | Anti-human natural killer cell inhibitory receptor group 2A protein (NKG2A) antibodies |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T03%3A56%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=Bezman,%20Natalie&rft.date=2022-03-15&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EUS11274150B2%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |